The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies
- PMID: 15630849
- DOI: 10.1016/j.clon.2004.06.007
The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies
Abstract
Aims: The debate on the funding and availability of cytotoxic drugs raises questions about the contribution of curative or adjuvant cytotoxic chemotherapy to survival in adult cancer patients.
Materials and methods: We undertook a literature search for randomised clinical trials reporting a 5-year survival benefit attributable solely to cytotoxic chemotherapy in adult malignancies. The total number of newly diagnosed cancer patients for 22 major adult malignancies was determined from cancer registry data in Australia and from the Surveillance Epidemiology and End Results data in the USA for 1998. For each malignancy, the absolute number to benefit was the product of (a) the total number of persons with that malignancy; (b) the proportion or subgroup(s) of that malignancy showing a benefit; and (c) the percentage increase in 5-year survival due solely to cytotoxic chemotherapy. The overall contribution was the sum total of the absolute numbers showing a 5-year survival benefit expressed as a percentage of the total number for the 22 malignancies.
Results: The overall contribution of curative and adjuvant cytotoxic chemotherapy to 5-year survival in adults was estimated to be 2.3% in Australia and 2.1% in the USA.
Conclusion: As the 5-year relative survival rate for cancer in Australia is now over 60%, it is clear that cytotoxic chemotherapy only makes a minor contribution to cancer survival. To justify the continued funding and availability of drugs used in cytotoxic chemotherapy, a rigorous evaluation of the cost-effectiveness and impact on quality of life is urgently required.
Comment in
-
The contribution of cytotoxic chemotherapy to the management of cancer.Clin Oncol (R Coll Radiol). 2005 Jun;17(4):294. doi: 10.1016/j.clon.2005.02.012. Clin Oncol (R Coll Radiol). 2005. PMID: 15997929 No abstract available.
Similar articles
-
A systematic overview of chemotherapy effects in colorectal cancer.Acta Oncol. 2001;40(2-3):282-308. doi: 10.1080/02841860151116367. Acta Oncol. 2001. PMID: 11441937 Review.
-
A systematic overview of chemotherapy effects in breast cancer.Acta Oncol. 2001;40(2-3):253-81. doi: 10.1080/02841860151116349. Acta Oncol. 2001. PMID: 11441936 Review.
-
Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer.J Natl Cancer Inst. 2012 Feb 8;104(3):211-27. doi: 10.1093/jnci/djr524. Epub 2012 Jan 20. J Natl Cancer Inst. 2012. PMID: 22266473 Free PMC article.
-
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.Cochrane Database Syst Rev. 2016 May 25;(5):CD010383. doi: 10.1002/14651858.CD010383.pub2. Cochrane Database Syst Rev. 2016. PMID: 27223332 Review.
-
A systematic overview of chemotherapy effects in ovarian cancer.Acta Oncol. 2001;40(2-3):340-60. doi: 10.1080/02841860151116420. Acta Oncol. 2001. PMID: 11441940 Review.
Cited by 62 articles
-
Thirty-Day Mortality After Curative and Palliative Anti-Cancer Treatment: Data Interpretation and Lessons for Clinical Implementation.Cancer Manag Res. 2020 Dec 1;12:12301-12308. doi: 10.2147/CMAR.S277924. eCollection 2020. Cancer Manag Res. 2020. PMID: 33293858 Free PMC article.
-
Reducing wait time for administration of systemic anticancer treatment (SACT) in a hospital outpatient facility.BMJ Open Qual. 2020 Oct;9(4):e000904. doi: 10.1136/bmjoq-2019-000904. BMJ Open Qual. 2020. PMID: 33023906 Free PMC article.
-
The Neurokinin-1 Receptor Antagonist Aprepitant: An Intelligent Bullet against Cancer?Cancers (Basel). 2020 Sep 20;12(9):2682. doi: 10.3390/cancers12092682. Cancers (Basel). 2020. PMID: 32962202 Free PMC article. Review.
-
The functional role of long noncoding RNA in resistance to anticancer treatment.Ther Adv Med Oncol. 2020 Jun 1;12:1758835920927850. doi: 10.1177/1758835920927850. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 32536982 Free PMC article. Review.
-
Human fibronectin extra domain B as a biomarker for targeted therapy in cancer.Mol Oncol. 2020 Jul;14(7):1555-1568. doi: 10.1002/1878-0261.12705. Epub 2020 Jun 15. Mol Oncol. 2020. PMID: 32386436 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical